Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: Role of thromboxane A2

Journal of Applied Physiology

Volumn 80, Issue 1, 1996, Pages 191-197

  Cuiper, Leslie L ^a   Price, Patricia V ^a   Christman, Brian W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

sheep; thromboxane A2 production

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID; IBUPROFEN; METHOXAMINE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DOSE RESPONSE; DYSPNEA; HEART DISEASE; HEART OUTPUT; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SHEEP; SYSTEMIC VASCULAR RESISTANCE; THROMBOCYTE ACTIVATION;

EID: 0030021420     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1996.80.1.191     Document Type: Article

References (22)

1. Belch, J. J. F., P. Newman, J. K. Drury, H. Capell, P. Leiberman, W. B. James, C. D. Forbes, and C. R. M. Prentice. Successful treatment of Raynaud's syndrome with prostacyclin. Thromb. Haemostasis 45: 255-256, 1981.
2. 2 in anesthetized dogs. Br. J. Pharmacol. 68: 437-447, 1980.
3. Christman, B. W., C. D. McPherson, J. H. Newman, G. A. King, G. R. Bernard, B. M. Groves, and J. E. Loyd. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327: 70-75, 1992.
4. Cuiper, L. L., C. M. Stein, A. J. J. Wood, and B. W. Christman. Rebound systemic vasoconstriction after abrupt prostacyclin cessation is not a result of sympatho-adrenal activation (Abstract). Am. J. Respir. Crit. Care Med. 151: A736, 1995.
5. 2) induces coronary vasodilation in anaesthetised dogs. Cardiovasc. Res. 12: 720-730, 1978.
6. Gerber, J. G., and A. S. Nies. Abrupt withdrawal of cardiovascular drugs. N. Engl. J. Med. 301: 1234-1235, 1979.
7. Higgenbottam, T. The place of prostacyclin in the clinical management of primary pulmonary hypertension. Am. Rev. Respir. Dis. 136: 782-785, 1987.
8. Higenbottam, T. W., D. Spiegelhalter, J. P. Scott, V. Fuster, A. T. Dinh-Xuan, N. Caine, and J. Wallwork. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br. Heart J. 70: 366-370, 1993.
9. Jones, D. K., T. W. Higgenbottam, and J. Wallwork. Long-term treatment for primary pulmonary hypertension with intravenous prostacyclin. Br. Heart J. 57: 270-278, 1987.
10. Jones, K., T. Higenbottam, and J. Wallwork. Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest 96: 784-789, 1989.
11. 2 in the human circulation. Anal. Biochem. 155: 198-205, 1986.
12. Oates, J. A., R. Whorton, J. F. Gerkens, R. A. Branch, J. W. Hollifield, and J. C. Frolich. The participation of prostaglandins in the control of renin release. Federation Proc. 38: 72-74, 1979.
13. Packer, M., J. Meller, N. Medina, R. Gorlin, and M. V. Herman. Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure. N. Engl. J. Med. 301: 1193-1197, 1979.
14. Patrono, C., F. Pugliese, G. Ciabattoni, P. Patrignani, A. Maseri, and S. Chierchia. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J. Clin. Invest. 69: 231-239, 1982.
15. Perlman, M. B., S. K. Lo, and A. B. Malik. Effect of prostacyclin on pulmonary vascular response to thrombin in awake sheep. J. Appl. Physiol. 60: 546-553, 1986.
16. Rubin, L. J., J. Mendoza, M. Hood, M. McGoon, R. Barst, W. B. Williams, J. H. Diehl, J. Crow, and W. Long. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann. Intern. Med. 112 485-491, 1990.
17. Smith, M. C., K. Danviriyasup, J. W. Crow, A. E. Cato, G. D. Park, A. Hassid, and M. J. Dunn. Prostacyclin substitution for heparin in long-term hemodialysis. Am. J. Med. 73: 669-678, 1982.
18. Swartz, R. D., W. Flamenbaum, A. Dubrow, J. C. Hall, J. W. Crow, and A. Cato. Epoprostenol during high risk hemodialysis: preventing further bleeding complications. J. Clin. Pharmacol. 28: 818-825, 1988.
19. Szczeklik, A., R. J. Gryglewski, R. Nizankowski, P. Skawinski, P. Gluszko, and R. Korbut. Prostacyclin therapy in peripheral arterial disease. Thromb. Res. 19: 191-199, 1980.
20. 2) in 108 patients with ischemic peripheral vascular disease. Prostaglandins 39: 657-664, 1990.
21. 2). Prostaglandins 17: 501-513, 1979.
22. Wheeler, A. P., W. D. Hardie, and G. R. Bernard. The role of cyclooxygenase products in lung injury induced by tumor necrosis factor in sheep. Am. Rev. Respir. Dis. 145: 632-639, 1992.